Capsulution Nanoscience AG and NanoDel Technologies GmbH have combined their business models under the name of Capsulution Pharma AG and created a company in the field of nanoparticle based drug delivery.

Subscribe to read...

IDM Pharma, Inc. has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) and the recommendation to grant centralized marketing authorization for mifamurtide (L-MTP-PE), known as MEPACT(R) in Europe, for the treatment of patients with non-metastatic, resectable osteosarcoma. Final approval from the European Commission is expected in early 2009 once the recommendation has been adopted at the next CHMP meeting.

Subscribe to read...